Palifermin After Haploidentical PBSCT

Phase 2

Withdrawn

• Conditions: Non-Hodgkin's Lymphoma or Hodgkin's Disease; Acute Leukaemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia; Osteomyelofibrosis
• Interventions: Other: Placebo; Drug: Palifermin

• Registration Number: NCT00570999
• Lead Sponsor: European Society for Blood and Marrow Transplantation

Brief Summary

This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are randomised to receive either placebo or a keratinocyte growth factor (Palifermin or Kepivance®).

The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also been suggested to have an ability to help improve the reconstitution, or development, of the immune system after the transplantation.

The hypothesis is that the patients T-cell dependent humoral immune response to recall antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo control group

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-12-10
• Study First Submitted QC: 2007-12-10
• Study First Posted: 2007-12-11
• Study Start: 2008-02
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-09
• Last Update Posted: 2012-05-10
• Study Completion: 2013-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Recipient:

• Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or complete remission
• ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1 or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS)
• CML in chronic or accelerated phase
• Osteomyelofibrosis (OMF)
• Hodgkin lymphoma (HD) in partial or complete remission
• Age ≥18 years, ≤ 65 years
• ECOG status ≤2
• Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior local radiotherapy is allowed except radiation involving the thymus
• Adequate pulmonary function
• Left ventricular ejection fraction (LVEF) >30%
• Haploidentical related donor
• Failure to find matched related or matched unrelated donor and urgently requiring transplantation
• Planned conditioning regimen per Aversa or Würzburg protocol
• Women must be post-menopausal, sterile or use effective contraception and have a negative pregnancy test at study entry (β-HCG neg)
• Signed informed consent

Donor:

• Healthy family member
• Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3 HLA allele(s) on the unshared haplotype
• Donors must be capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central venous catheter should leukapheresis via peripheral vein be inadequate.
• Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell collection or should patient fail to demonstrate sustained engraftment
• Signed informed consent

Exclusion Criteria

Recipient:

• History of or concurrent cancer (< 5 years ago) other than those named in inclusion criteria
• Primary chemorefractory disease
• CML in blast crisis
• MM with no or minor response to previous treatment
• Prior treatment with palifermin, or other keratinocyte growth factors
• Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component of the product
• Documented hypersensitivity to Prevenar vaccine or its components
• Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous transplantation
• Prior total body irradiation
• Post thymectomy
• Major anticipated illness or organ failure incompatible with survival from PBPC transplantation
• Active chronic skin disease requiring therapy
• Active inflammatory bowel disease requiring therapy
• Active uncontrolled infection
• Sero-positive HIV
• Pregnancy or breast-feeding
• Active invasive fungal tissue infection (EORTC criteria)
• 30 days or less since receiving an investigational product or device in another clinical trial
• Concurrent enrolment in another trial is not permitted unless the purpose is for long-term follow-up/survival data only, or observational only
• Chronic pancreatitis or history of acute pancreatitis within 1 year prior to transplant
• Psychiatric disorder associated with incompliance
• Myocardial infarction less than 3 months pre enrolment or EF <30% as measured in echocardiography/laevoventriculography
• Infusion of retrovirally or other transduced cells are not permitted.
• Planned intravenous application of immunoglobulins is contraindicated throughout the study period.
• Donor lymphocyte infusions are not allowed.

Donor:

• A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis infection.
• Evidence of any other active infection
• Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders, chronic inflammatory diseases) posing a health risk for peripheral blood stem cell harvest
• Hematopoietic or marrow function related disease interfering with the collection of sufficient numbers of normal progenitor cells
• Pregnancy or breast-feeding
• Any malignancy besides basal cell epithelioma or cured malignancy < 5 years ago
• Psychiatric disorder associated with incompliance

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B	Placebo	Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
Arm A	Palifermin	Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).

Primary Outcome Measures

Name	Time	Method
To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)	at study day +270 (20 days after the third Prevenar injection)

Secondary Outcome Measures

Name	Time	Method
To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation	Study days +210, +240, +270
To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections	at 2 years
To assess drug related safety	at 2 years

Trial Locations

Locations (1)

Dr Ruth Seggewiss; 🇩🇪 Würzburg, Germany